8-K
PERKINELMER INC false 0000031791 0000031791 2020-03-25 2020-03-25 0000031791 pki:Commonstock1parvaluepershareMember 2020-03-25 2020-03-25 0000031791 pki:M1.875NotesDue2026Member 2020-03-25 2020-03-25 0000031791 pki:M0.600NotesDue2021Member 2020-03-25 2020-03-25

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): March 25, 2020

 

PerkinElmer, Inc.

(Exact Name of Registrant as Specified in its Charter)

 

Massachusetts

 

001-05075

 

04-2052042

(State or Other Jurisdiction

of Incorporation or Organization)

 

(Commission

File Number)

 

(IRS Employer

Identification No.)

940 Winter Street, Waltham, Massachusetts

 

02451

(Address of Principal Executive Offices)

 

(Zip Code)

Registrant’s telephone number, including area code: (781) 663-6900

Not applicable.

(Former Name or Former Address, if Changed Since Last Report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

  Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

  Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

  Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

  Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

 

Trading

Symbol(s)

 

Name of each exchange

on which registered

Common stock, $1 par value per share

 

PKI

 

The New York Stock Exchange

1.875% Notes due 2026

 

PKI 21A

 

The New York Stock Exchange

0.600% Notes due 2021

 

PKI 21B

 

The New York Stock Exchange

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  

 

 


Item 7.01 Regulation FD Disclosure.

In response to anticipated investor questions regarding the press release issued by PerkinElmer, Inc. (the “Company”) on March 24, 2020 announcing the U.S. Food and Drug Administration’s Emergency Use Authorization (EUA) approval of the Company’s new Coronavirus RT-PCR test, the Company expects to provide information that to address growing supply constraints worldwide, it has expanded the production capacity of its extraction and RT-PCR tests at its global facilities and has the capability to ship millions of these solutions to its customers.    


SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

PERKINELMER, INC.

             

Date: March 25, 2020

 

 

By:

 

/s/ Joel S. Goldberg

 

 

 

Joel S. Goldberg

 

 

 

Senior Vice President, Administration, General Counsel and Secretary